Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update
May 3, 2022– Webcast to be Held at 8:00 am ET on May 10, 2022 – NEW YORK, May 3, 2022 – Immunic,…Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences
April 25, 2022NEW YORK, April 25, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer
March 16, 2022NEW YORK, March 16, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. to Participate in Investor and Scientific Conferences in March
March 8, 2022NEW YORK, March 8, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity
February 24, 2022– Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort…Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn’s and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis
February 18, 2022– Top-Line Data of the CALDOSE-1 Trial Expected to be Available in June of 2022 – NEW YORK, February 18,…Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update
February 17, 2022– Webcast to be Held at 8:00 am ET on February 24, 2022 – NEW YORK, February 17, 2022 – Immunic,…Immunic, Inc. to Participate in Investor and Scientific Conferences in February
February 8, 2022NEW YORK, February 8, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
February 2, 2022NEW YORK, February 2, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…